Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Breast Cancer
Benefits and Risks of Mammography Explored in New Analyses
By
Rosemary Frei, MSc
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
According to a new systematic review of the risks and benefits of breast cancer screening, regular mammography is associated with a 19% reduction in breast cancer mortality, but it is also associated with a 61% cumulative risk of a false-positive result, and approximately 19% of the cases are, in fact, considered overdiagnoses (Pace LE, Keating NL.
JAMA
. 2014;311:1327-1335).
Read Article
New Guidelines Expand Pool of Patients Eligible for Sentinel Node Biopsy
By
Alice Goodman
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
The American Society of Clinical Oncology (ASCO) has issued new guidelines for the use of sentinel node biopsy (SNB) in patients with early-stage breast cancer (Lyman GH, et al.
J Clin Oncol
. 2014;32:1365-1383. The newer version expands the use of SNB to a larger group of patients, based on evidence from 9 randomized trials and 13 cohort studies conducted since 2005, when the first SNB guidelines were published.
Read Article
Large Study Supports Early Oophorectomy for BRCA Mutation Carriers
By
Alice Goodman
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2014, Vol 5, No 2
Women who carry the
BRCA1
or
BRCA2
mutation had an 80% reduction in risk for ovarian, fallopian tube, or breast cancer if they underwent preventive oophorectomy, according to a large prospective study, and a 77% reduction in all-cause mortality (Finch AP, et al.
J Clin Oncol
. 2014 February 24 [Epub ahead of print]).
Read Article
I-SPY 2: First Results Based on Biomarkers/Genetic Signatures in Breast Cancer
Breast Cancer
,
Personalized Medicine
February 2014, Vol 5, No 1
San Antonio, TX—Veliparib plus carboplatin was identified as a worthy combination to move forward in trials of patients with triple-negative breast cancer (TNBC; ie, estrogen receptor–negative, progesterone receptor–negative, HER2-negative), a subtype of breast cancer with a very poor prognosis.
Read Article
PIK3CA Mutation Thwarts Neoadjuvant Anti-HER2 Therapy in Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Personalized Medicine
February 2014, Vol 5, No 1
>San Antonio, TX—Patients with HER2-positive breast cancer harboring a PIK3CA mutation had a significantly lower likelihood of achieving a pathologic complete response (pCR) to neoadjuvant anti-HER2 therapy, the results of 2 large clinical trials presented at the 2013 San Antonio Breast Cancer Symposium (SABCS) showed.
Read Article
Comparative Effectiveness Research Should Reap Benefits for Oncology Care
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Comparative effectiveness research (CER) is an important construct for identifying and summarizing the evidence on the effectiveness, safety, and overall value of alternative strategies in oncology care, said Gary H. Lyman, MD, MPH, Professor of Medicine, Duke University and the Duke Cancer Research Institute, Durham, NC, during the 2013 Breast Cancer Symposium.
Read Article
Current Patterns and Costs of Treating Patients with Metastatic Breast Cancer
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—In a population of patients with metastatic breast cancer and Medicare Part D claims, the mean lifetime cost of treatment was approximately $102,000, according to a study presented at the 2013 Breast Cancer Symposium by Hope S. Rugo, MD, Director, Breast Oncology Clinical Trials Program, University of California, San Francisco.
Read Article
Role of Radiation and Imaging in DCIS Explained
By
Phoebe Starr
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Management of ductal carcinoma in situ (DCIS) was the focus of 2 studies highlighted at a press conference before the 2013 Breast Cancer Symposium.
Read Article
For Oncologists, Some Food for Thought in the New Era of Healthcare Reform
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—At the 2013 Breast Cancer Symposium, Lawrence N. Shulman, MD, Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, told oncologists that in the current era of healthcare reform, they will need to think beyond treatment outcomes, toxicities, and personal preferences.
Read Article
ASCO Adds Aromatase Inhibitor to Breast Cancer Prevention Options in Postmenopausal Women
By
Charles Bankhead
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
September 2013, Vol 4, No 7
An aromatase inhibitor has joined tamoxifen (Nolvadex) and the selective estrogen receptor (ER) modulator raloxifene hydrochloride (Evista) as chemoprevention for women who are at an increased risk for breast cancer, according to the recent update of the American Society of Clinical Oncology (ASCO) practice guideline (Visvanathan K, et al.
J Clin Oncol
. 2013;31:2942-2962)
Read Article
Page 10 of 13
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma